Liu Y, Wang R
BMC Gastroenterol. 2025; 25(1):106.
PMID: 39994578
PMC: 11849289.
DOI: 10.1186/s12876-024-03544-w.
Fu W, Zhao J, Cheng G, Xu L, Lyu L, Ding Y
BMC Gastroenterol. 2025; 25(1):102.
PMID: 39984858
PMC: 11846309.
DOI: 10.1186/s12876-024-03585-1.
Zhang J, Ran S, Wei S, Tian F, Chen L, Yang Z
Ecotoxicol Environ Saf. 2025; 291:117893.
PMID: 39955868
PMC: 11860302.
DOI: 10.1016/j.ecoenv.2025.117893.
Bril F, Berg G, Barchuk M, Nogueira J
J Lipid Atheroscler. 2025; 14(1):5-29.
PMID: 39911965
PMC: 11791423.
DOI: 10.12997/jla.2025.14.1.5.
Cammisotto V, Valeriani E, Pignatelli P, Violi F
Antioxidants (Basel). 2025; 14(1.
PMID: 39857417
PMC: 11763266.
DOI: 10.3390/antiox14010083.
Association of diet quality scores with risk of metabolic-associated fatty liver disease in Iranian population: a nested case-control study.
Taheri E, Yilmaz Y, Ghorat F, Moslem A, Zali M
J Diabetes Metab Disord. 2025; 24(1):46.
PMID: 39816985
PMC: 11729581.
DOI: 10.1007/s40200-024-01544-x.
Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD).
Mignini I, Galasso L, Piccirilli G, Calvez V, Termite F, Esposto G
Antioxidants (Basel). 2025; 13(12.
PMID: 39765860
PMC: 11727446.
DOI: 10.3390/antiox13121532.
Associations of Metabolic Dysfunction-Associated Fatty Liver Disease With Peripheral Artery Disease: Prospective Analysis in the UK Biobank and ARIC Study.
Liu Y, Wang J, Jin R, Xu Z, Zhao X, Li Y
J Am Heart Assoc. 2024; 13(22):e035265.
PMID: 39547959
PMC: 11681420.
DOI: 10.1161/JAHA.124.035265.
The possible protective effect of luteolin on cardiovascular and hepatic changes in metabolic syndrome rat model.
Fikry H, Saleh L, Sadek D, Alkhalek H
Cell Tissue Res. 2024; 399(1):27-60.
PMID: 39514020
DOI: 10.1007/s00441-024-03927-1.
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.
Suoh M, Esmaili S, Eslam M, George J
Hepatol Int. 2024; 18(6):1740-1755.
PMID: 39412611
PMC: 11632019.
DOI: 10.1007/s12072-024-10731-0.
Rodent model of metabolic dysfunction-associated fatty liver disease: a systematic review.
Cui X, Li H, Li L, Xie C, Gao J, Chen Y
J Gastroenterol Hepatol. 2024; 40(1):48-66.
PMID: 39322221
PMC: 11771679.
DOI: 10.1111/jgh.16749.
Comprehensive analysis of shared risk genes and immunity-metabolisms between non-alcoholic fatty liver disease and atherosclerosis via bulk and single-cell transcriptome analyses.
Hu Q, Luo Y, He H, Chen H, Liao D
Heliyon. 2024; 10(15):e35453.
PMID: 39165965
PMC: 11334902.
DOI: 10.1016/j.heliyon.2024.e35453.
Identifying the most critical behavioral lifestyles associated with MAFLD: evidence from the NHANES 2017-2020.
Li S, Chen J, Zhang Y, Huang S, Pan Q, Tang D
Front Endocrinol (Lausanne). 2024; 15:1375374.
PMID: 39119002
PMC: 11307443.
DOI: 10.3389/fendo.2024.1375374.
Gut mycobiome alterations and implications for liver diseases.
Zeng S, Schnabl B
PLoS Pathog. 2024; 20(8):e1012377.
PMID: 39116092
PMC: 11309506.
DOI: 10.1371/journal.ppat.1012377.
The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD.
Yang Z, Yang J, Cai J, Zhang X, Zhang P, She Z
Rev Cardiovasc Med. 2024; 24(6):157.
PMID: 39077530
PMC: 11264127.
DOI: 10.31083/j.rcm2406157.
Anthocyanins as Adjuvant Treatment for Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Khan N, Zurayyir E, Almuslem M, Alshamrani R, Alamri R, Sulaimani G
Cureus. 2024; 16(6):e63445.
PMID: 39077306
PMC: 11285696.
DOI: 10.7759/cureus.63445.
Roles of lipid droplets and related proteins in metabolic diseases.
Zhang Z, Yu Z, Liang D, Song K, Kong X, He M
Lipids Health Dis. 2024; 23(1):218.
PMID: 39030618
PMC: 11264848.
DOI: 10.1186/s12944-024-02212-y.
From NAFLD to MASLD: Meta-analysis and systematic review of NAFLD patients in Turkiye in terms of metabolic profile and MASLD potential.
Akdas S, Yazihan N
Hepatol Forum. 2024; 5(3):126-138.
PMID: 39006144
PMC: 11237240.
DOI: 10.14744/hf.2023.2023.0042.
Effects of Leaf Extract on Liver Histopathology: A Systematic Review.
Nurhayati T, Ridho M, Santoso P, Setiawan S, Goenawan H, Tarawan V
J Nutr Metab. 2024; 2024:6815993.
PMID: 38993633
PMC: 11239234.
DOI: 10.1155/2024/6815993.
Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
Imai J, Takashimizu S, Suzuki N, Ohshinden K, Sawamoto K, Mishima Y
Sci Rep. 2024; 14(1):13411.
PMID: 38862756
PMC: 11166940.
DOI: 10.1038/s41598-024-64301-3.
